Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Roberto Pinckevicius"'
Autor:
Francisco Lastiri, Marcelo Muino, José Luis Castilla, S. Jovtis, Luis Balbiani, Mariana Abal, Roberto Pinckevicius, Adolfo Marantz, D. Lewi, Silvia Agusto, Eduardo Almira, Graciela Pasccon, Graciela Uranga, Luis Fein, Mónica Reale
Publikováno v:
Seminars in Oncology. 28:44-49
The primary goal of this phase II study was to determine the efficacy of gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) plus 5-fluorouracil in patients with pancreatic cancer. Eligibility criteria included nonresectable locally advance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::afdd06435c283d0bba23ac99a62798be
https://doi.org/10.1016/s0093-7754(01)80008-7
https://doi.org/10.1016/s0093-7754(01)80008-7
Autor:
Adolfo Marantz, Silvia Jovtis, Eduardo Almira, Luis Balbiani, Jos[eacute] Luis Castilla, Luis Fein, Daniel Lewi, Graciela Pasccon, Roberto Pinckevicius, Graciela Uranga, Mariana Abal, Marcelo Mui[ntilde]o, M[oacute]nica Reale, Silvia Agusto
Publikováno v:
Seminars in oncology. 28(3 Suppl 10)
The primary goal of this phase II study was to determine the efficacy of gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) plus 5-fluorouracil in patients with pancreatic cancer. Eligibility criteria included nonresectable locally advance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d652cee753cd9e5f520a8770a59e6936
https://pubmed.ncbi.nlm.nih.gov/11510033
https://pubmed.ncbi.nlm.nih.gov/11510033